Persistence of antibody to hepatitis B surface antigen after low-dose, intradermal hepatitis B immunization and response to a booster dose

Bryan, Joe P.; Sjögren, Maria H.; MacArthy, Philip; Cox, Elizabeth; Legters, Llewellyn J.; Perine, Peter L.

doi:10.1016/0264-410x(92)90416-h

Cited by 20 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This fact represents clear evidence of the presence of immunologic memory induced by the first vaccination eight years before. The authors cited above (Bryan et al 1992, Jaiswal et al 1995, Kurugöl et al 2001, who reported a shorter persistence of immunity to hepatitis B than that observed in the present study, i.e., two, three, and five years after the first vaccination, respectively, also observed a booster effect after intradermal application of a booster dose to previously seropositive individuals whose serum anti-HBs titer had been lower than 10 mIU/ml. As mentioned, evidence of the induction of immunologic memory by a first vaccination has also been obtained after intramuscular vaccination with usual doses of recombinant and human plasmaderived vaccines.…”

Section: Discussioncontrasting

confidence: 38%

“…However, few studies have been published concerning the persistence of immunity conferred by HB vaccination with low doses administered intradermally using the same regimen. Bryan et al (1992) demonstrated that protection (anti-HBs ≥ 10 mIU/ml) conferred by the application of three 2 µg doses of the North-American vaccine obtained from human plasma (Heptavax-B, Merck Sharp & Dohme) in the same regimen as used here (0, 1, and 6 months) persisted in 97% of vaccinees for 14 months and in 89% for 25 months; application of a booster dose in the 16 individuals who had not seroconverted induced protective serum anti-HBs levels in 69%. Jaiswal et al (1995) showed the persistence of immunity in 93.3% of 200 adults who had seroconverted three years before, after intradermal application of three 4 µg doses of human plasma vaccine in the same regimen as cited above; a booster effect resulting from the intradermal administration of a complementary dose (4 µg) of the same vaccine was observed in 27 individuals who had become non-reactive.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intradermal vaccination of adults with three low doses (2 µg) of recombinant hepatitis B vaccine. II. Persistence of immunity and induction of immunologic memory

Elisbão

Baldy

Bonametti

et al. 2003

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Of the 110 dentists who had presented seroconversion 50 days after the intradermal application of three 2 µg doses of the Belgian recombinant vaccine against hepatitis B (HB), or latent HBV infection during the eight years following the first vaccination. A 2 µg booster dose was administered intradermally to eight dentists with anti-HBs titers lower than 10 mIU/ml (non-responders) and to six dentists with titers ranging from 10 to 100 mIU/ml (poor responders); the determination of anti-HBs one month later demonstrated the occurrence of seroconversion in the eight non-responders and an increase in anti-HBs titer in the six poor responders. In summary, the present results demonstrated the prolonged persistence of protection against HBV infection and the development of immunologic memory provided by vaccination against HB -with intradermal application of three 2 µg doses of the Belgian recombinant vaccine at 0, 1, and 6 months -carried out eight years before in 51 dentists.Key words: hepatitis B vaccine -seroconversion -immunologic memoryThe immunogenicity and safety of hepatitis B (HB) vaccines -both recombinant and derived from human plasma administered intramuscularly in three doses at standard intervals (0, 1, and 6 months) -are similar and have been widely confirmed (Szmuness et al. 1980, 1982, Stevens et al. 1985, Zajac et al. 1986, Lee et al. 1995. In addition to high seroprotection rates, several studies have demonstrated prolonged persistence of immunity against HB (Hadler et al. 1986, Stevens et al. 1985, Ding et al. 1993, Greenberg 1993, Lieming et al. 1993, Tabor et al. 1993, Wainwright et al. 1997, Wu et al. 1999, Dexter et al. 2002, Whittle et al. 2002 and the development of immunologic memory (Gonzalez et al. 1993, Lai et al. 1993, Resti et al. 1993, Trivello et al. 1995, West & Calandra 1996, Da Villa et al. 1997, Li et al. 1998, Shih et al. 1999 Banatvala et al. 2001, Watson et al. 2001, Dexter et al. 2002 as a result of the intramuscular application of both recombinant and human plasma-derived HB vaccines to adults and children using the scheme cited above. Banatvala et al. (2001) referred to four studies carried out with recombinant vaccines administered intramuscularly to adults and children using habitual doses and regimens, in which five to eight years after vaccination the serum anti-HBs titer was equal to or higher than 10 mIU/ml in 83% to 93% of the vaccinees. Watson et al. (2001), evaluating the response to intramuscular application of a booster dose of recombinant HB vaccine 13 years after the application of three usual doses at 0, 1, and 6 months, demonstrated the presence of immunologic memory in all individuals studied (18 vaccinated during childhood and seven vaccinated at more than 30 years of age).However, only few and short-term studies are available regarding the duration of immunity conferred by HB vaccine administered by the intradermal route. Thus, the objective of the present study was to determine the persistence of immunity conferred by recombinant HB vaccine administered in...

show abstract

Section: Discussioncontrasting

confidence: 38%

Section: Discussionmentioning

confidence: 99%

Intradermal vaccination of adults with three low doses (2 µg) of recombinant hepatitis B vaccine. II. Persistence of immunity and induction of immunologic memory

Elisbão

Baldy

Bonametti

et al. 2003

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…Overall, 73/76 (96%) of students in the second group had protective concentrations of antibody after the booster dose (Bryan et al, 1992).…”

Section: Discussionmentioning

confidence: 99%

Evaluating the Effect of Booster Dose of Hepatitis B Vaccine in Low-and Non-Responders Healthcare Workers and the Role of some Host-Related Factors

Chia-Yon¹

2011

American Journal of Immunology

View full text Add to dashboard Cite

Problem statement: Hepatitis B comprises one of the major health problems worldwide. Health Care Workers (HCW) are a group at risk for Hepatitis B Virus (HBV) infection. Infection with hepatitis B virus has become a vaccine-preventable disease. Vaccination against Hepatitis B Virus infection (HBV) is safe and effective. The aim of this study is evaluation the immunologic response of booster dose of Hepatitis B vaccine in none and low responder health care workers and effects of some host-related factors. Approach: In a cross sectional descriptive analytic study carried out on the medical staff of Tabriz Shahid Madani Hospital in 2009-2010, we evaluated the immunologic response of booster dose of Hepatitis B vaccine in none and low responder health care workers and effects of some host-related factors. Results: Of 331 studied health care workers, 123 people (37.2%) were male and 208 people (62.8%) female. The mean antibody titer in the studied medical staff was 304.07±199.98 IU L −1 in the range of 0-1000 and median of 330. Dividing the antibody titer into three groups of "no response" (Titer<10 IU L −1 ), "Low response" (Titer10-100 IU L −1 ) and "Good response"(Titer>100 IU L −1 ) revealed that from 331 studied staff, 31 people (9.4%) were in "no response" group, 40 people (12.1%) in "Low response" group and 260 people (78.59%) in "Good response" group and after one booster dose of vaccine in none and low responder group, 7 people (2.1%) were in "no response" group, 5 people (1.5%) in "Low response" group and 319 people (96.4%) in "Good response" group. Conclusion: One booster dose of vaccine in people with low and none Response to hepatitis B vaccination cause to significantly increase of antibody titer so that, Good response rate increase from 78.5-96.4% and low response rate decrease from 12.1-1.5% and none response rate decrease from 9.4-2.1%. Use one booster dose of vaccine recommended in people with antibody titer blow 100.

show abstract

“…화장 품은 물 또는 기름을 주성분으로 구성되며 부가적인 성분으로 글리세틴, 솔비톨, 아미노산 유도체, 단백질 등을 배합하여 제조하는데 [6,7], 이러한 성분들은 미 생물의 생육에 있어 용이한 환경으로 미생물에 의하 여 화장품의 침전, 변질, 변패 등을 일으킨다 [8,9] 전자공여능 (%) = ( 1 -As / Ac ) × 100…”

unclassified

Enhancement of the Cosmeceutical Activity by Nano-encapsulation of Thiamine Di-lauryl Sulfate (TDS) with antimicrobial efficacy

서용창¹,

노라환²,

권희석³

et al. 2013

Journal of the Society of Cosmetic Scientists of Korea

View full text Add to dashboard Cite

This study was to improve cosmetical activity of thiamine di-lauryl sulfate (TDS) by encapsulation of nanoparticle with lecithin. Results showed that most of the nanoparticles containing the TDS were well formed in round shape with below 150 ∼ 200 nm diameter as well as they were fairly stable in various pH ranges by measuring zeta potentials. The nanoparticles of TDS resulted in 85% cell viability of human normal fibroblast cells (CCD-986sk) when added at the highest concentration (1.0 mg/mL). The nanoparticles of Acer mono sap showed highest free radical scavengering effect as 88.1% in adding sample (1.0 mg/mL), compared to TDS solution of non-encapsulation (81.6%). The nanoparticles of TDS reduced the expression of MMP-1 on UV-irradiated CCD-986sk cells down to as 41.4%. The TDS solution and nanoparticles showed significant anti-microbial activities agaionst the salmonella typhimurium and listeria monocytogenes at 5 and 6 days as compared with control. Anti-microbial activities of TDS nanoparticles were similar to positive control. These results indicated that TDS nanoparticles may be a source for functional cosmetic agents capable of improving cosmetical activity such as antioxidant, whitening, and anti-wrinkling effects and can be further developed as natural preservative in cosmetics.

show abstract

Persistence of antibody to hepatitis B surface antigen after low-dose, intradermal hepatitis B immunization and response to a booster dose

Cited by 20 publications

References 32 publications

Intradermal vaccination of adults with three low doses (2 µg) of recombinant hepatitis B vaccine. II. Persistence of immunity and induction of immunologic memory

Intradermal vaccination of adults with three low doses (2 µg) of recombinant hepatitis B vaccine. II. Persistence of immunity and induction of immunologic memory

Evaluating the Effect of Booster Dose of Hepatitis B Vaccine in Low-and Non-Responders Healthcare Workers and the Role of some Host-Related Factors

Enhancement of the Cosmeceutical Activity by Nano-encapsulation of Thiamine Di-lauryl Sulfate (TDS) with antimicrobial efficacy

Contact Info

Product

Resources

About